CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
Frovatriptan +1 moredrug
Likely dose
Frovatriptan 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01044251
NCT01044251Phase 2Completed

Frovatriptan as a Transitional Therapy in Medication Overuse Headache

University of Calgary·interventional·Posted Jan 7, 2010·Updated Apr 18, 2019

In Brief

A Phase 2 clinical trial evaluating Frovatriptan and Placebo for Medication Overuse Headache and Analgesic Overuse Headache. Completed, enrolled 55 participants across 1 site.

Detailed Summary

This study will analyze the effectiveness of a medication called Frovatriptan, in the context of medication overuse headache (MOH). MOH is a headache that develops when pain-killers are taken frequently. The treatment is to stop the overuse of these pain-killers, but that can sometimes worsen the headache first before it gets better. We are testing Frovatriptan against placebo to see if it can help patients with this transition and avoid the worsening of the headache that can occur. We will also see if Frovatriptan can help in other ways, such as maintain patients free of medication overuse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 7, 2010
Enrollment StartJan 1, 2010
Primary CompletionApr 17, 2019
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 16.5 years ago

Interventions

Frovatriptandrug

2.5 mg po bid for 10 days

Placebodrug

1 tab po bid for 10 days